The relative mechanisms include the HER2 and MET amplifications, as observed in in vitro studies, but also the combination of the KRAS G12D mutation and PTEN loss, and CDCP1 or AXL RNA overexpression, as reported in some NSCLC patients (11–13). The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.